NCT06102447View on ClinicalTrials.gov

Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
DRUG

Netopitam Palonosetron capsules and dexamethasone

On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.

Trial Locations (1)

610041

Sichuan Cancer Hospital and Research Institute, Chengdu

All Listed Sponsors
lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT06102447 - Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter